IQVIA Holdings Inc. (IQV) — 分析摘要
IQVIA Holdings Inc.（IQV）的市值为34.64十亿美元，最近一年的营收同比增长了+5.9%。净利润率为8.3%。当前市盈率为25.0倍。
核心要点
- 营收同比变化+5.9%
- 净利润率8.3%
- 市盈率25.0倍
与SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH板块的其他公司相比，IQV的营收增长为+5.9%，市盈率为25.0倍。
IQVIA Holdings Inc. (IQV)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 4.7x — 杠杆偏高
利息保障倍数为 2.9x — 应对盈利下滑空间有限
流动比率为 0.75x — 流动负债超过流动资产
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
行业
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
员工人数
93,000
总部
DURHAM, NC
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。